Headlines: Cybalta Approved for Anxiety; iPhone Apps for Diabetics, Hearing Impaired
Monday, November 30th, 2009
INDIANAPOLIS – The U.S. Food and Drug Administration approved Eli Lilly’s Cymbalta (duloxetine HCl) for treatment of generalized anxiety disorder.
“Since generalized anxiety disorder can be a chronic illness, it is important that doctors and their patients find a treatment option that is effective in both the acute and maintenance phase of treatment,” said James M. Martinez, MD, U.S. Medical Director for Cymbalta, in a press release to PR Newswire. “With this additional approval, Cymbalta offers a new option for the maintenance treatment of this often-debilitating condition.” Cymbalta is made by Eli Lilly and Company (NYSE: LLY) of Indianapolis.
Other headlines in the field of health safety and recall include:
- Is there a history lesson from the swine flu of ’76? As more and more people receive the H1N1 shot, The Washington Post‘s David Brown looks at an earlier vaccine that is casting a public shadow over the attempt to immunize 200 million people in the next few months.
- Top iPhone apps for healthcare pros and their patients listed. Apps for the iPhone and iPod Touch can help healthcare pros provide better treatment, and help individuals lose weight, exercise and manage diabetes, Information Week reports. Apps include Epocrates, which keeps health data; SoundAMP, which turns an iPhone into a hearing aid; and Islet, a diabetic resource.

RICHMOND – It seems backwards, testing a drug for safety after it has been approved. But some researchers now are beginning to see the benefits.
WASHINGTON – A massive crib recall will have millions of Americans checking their cribs over the holidays.
FALLS CHURCH – A leading official in the field of medicine and health information technology will speak at Noblis Dec. 15 at a free breakfast meeting sponsored by the
ROCHESTER, Minn. – In a major study by the Mayo Clinic, nearly one out of 10 surgeons had reportedly made a major medical error related to burnout in the last three months.
PHILADELPHIA – Pediatric immunologist Jordan S. Orange, M.D., Ph.D. of
NATICK, Mass. – 